- Home
- MGRM vs UNCY Comparison
MGRM vs UNCY Comparison
Compare MGRM & UNCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGRM
- UNCY
- Stock Information
- Founded
- MGRM 2016
- UNCY 2016
- Country
- MGRM United States
- UNCY United States
- Employees
- MGRM N/A
- UNCY N/A
- Industry
- MGRM Medical/Dental Instruments
- UNCY Biotechnology: Pharmaceutical Preparations
- Sector
- MGRM Health Care
- UNCY Health Care
- Exchange
- MGRM Nasdaq
- UNCY Nasdaq
- Market Cap
- MGRM 79.9M
- UNCY 91.0M
- IPO Year
- MGRM N/A
- UNCY 2021
- Fundamental
- Price
- MGRM $5.83
- UNCY $4.62
- Analyst Decision
- MGRM Strong Buy
- UNCY Strong Buy
- Analyst Count
- MGRM 1
- UNCY 4
- Target Price
- MGRM $5.40
- UNCY $63.75
- AVG Volume (30 Days)
- MGRM 810.3K
- UNCY 1.2M
- Earning Date
- MGRM 08-13-2025
- UNCY 08-13-2025
- Dividend Yield
- MGRM N/A
- UNCY N/A
- EPS Growth
- MGRM N/A
- UNCY N/A
- EPS
- MGRM N/A
- UNCY N/A
- Revenue
- MGRM N/A
- UNCY N/A
- Revenue This Year
- MGRM N/A
- UNCY N/A
- Revenue Next Year
- MGRM N/A
- UNCY $1,458.53
- P/E Ratio
- MGRM N/A
- UNCY N/A
- Revenue Growth
- MGRM N/A
- UNCY N/A
- 52 Week Low
- MGRM $1.92
- UNCY $2.02
- 52 Week High
- MGRM $6.02
- UNCY $11.00
- Technical
- Relative Strength Index (RSI)
- MGRM 93.59
- UNCY 40.60
- Support Level
- MGRM $2.81
- UNCY $4.31
- Resistance Level
- MGRM $6.02
- UNCY $5.55
- Average True Range (ATR)
- MGRM 0.19
- UNCY 0.57
- MACD
- MGRM 0.29
- UNCY -0.08
- Stochastic Oscillator
- MGRM 94.70
- UNCY 10.92
About MGRM Monogram Orthopaedics Inc.
Monogram Technologies Inc develops a product solution architecture to enable patient-optimized orthopedic implants at scale by linking 3D printing and robotics with advanced pre-operative imaging. The company has a robot prototype that can autonomously execute optimized paths for high-precision insertion of implants in synthetic bone specimens. Monogram also intends to produce and market robotic surgical equipment and related software, orthopedic implants, tissue ablation tools, navigation consumables, and other miscellaneous instrumentation necessary for reconstructive joint replacement procedures.
About UNCY Unicycive Therapeutics Inc.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.